SCD and colonic neoplasm: Finally, we showed that SCD1 was an attractive target for combination immunotherapy because treatment with a SCD1 inhibitor augmented the antitumor effects of anti-PD-1 antibody, and SCD1 was a potential biomarker as suggested by high expression of SCD1 in non-T cell inflamed human colon cancers and the correlation of serum SCD1-related fatty acids with the responses to anti-PD-1 antibody in NSCLC patients.